NASDAQ:TRVI Trevi Therapeutics Q3 2024 Earnings Report $6.07 -0.03 (-0.49%) Closing price 04/17/2025 04:00 PM EasternExtended Trading$6.04 -0.03 (-0.41%) As of 04/17/2025 06:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Earnings HistoryForecast Trevi Therapeutics EPS ResultsActual EPS-$0.13Consensus EPS -$0.12Beat/MissMissed by -$0.01One Year Ago EPS-$0.08Trevi Therapeutics Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/ATrevi Therapeutics Announcement DetailsQuarterQ3 2024Date11/6/2024TimeAfter Market ClosesConference Call DateWednesday, November 6, 2024Conference Call Time4:30PM ETUpcoming EarningsTrevi Therapeutics' Q1 2025 earnings is scheduled for Tuesday, May 6, 2025, with a conference call scheduled at 4:30 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.Q1 2025 Earnings ReportConference Call ResourcesConference Call AudioConference Call TranscriptPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Trevi Therapeutics Q3 2024 Earnings Call TranscriptProvided by QuartrNovember 6, 2024 ShareLink copied to clipboard.There are 10 speakers on the call. Operator00:00:00Good afternoon, and welcome to the Trevi Therapeutics Third Quarter 2024 Earnings Conference Call. At this time, all participants will be in listen only mode. After today's presentation, there will be an opportunity to ask questions. Please note this event is being recorded. Various remarks that management makes during this conference call about the company's future expectations, plans and prospects constitute forward looking statements for purposes of the Safe Harbor provisions under the Private Securities Litigation Reform Act of 1995. Operator00:00:50Actual results may differ materially from those indicated by these forward looking statements as a result of various important factors, including those discussed in the Risk Factors section of the company's most recent quarterly report on Form 10 Q, which the company filed with the SEC this afternoon. In addition, any forward looking statements represent the company's views only as of today and should not be relied upon as representing the company's views as of any subsequent date. While the company may elect to update these forward looking statements at some point in the future, the company specifically disclaims any obligation to do so, even if its views change. I would now like to turn the conference call over to Jennifer Goode, Trevy's President and CEO. Please go ahead. Speaker 100:01:41Good afternoon, and thank you for joining us for our Q3 2024 earnings call and business update. Joining me today on this call are my colleagues Lisa Delfini, Trevy's Chief Financial Officer and Doctor. James Casella, Trevy's Chief Development Officer. I will give an update on our trials and upcoming data milestones and Lisa will give a brief financial update. Then the 3 of us are happy to answer any questions. Speaker 100:02:07First, I would like to take a minute and introduce you to Jim Casella, who has recently joined our leadership team as our Chief Development Officer. As some of you may know, Jim has been on our Board of Directors for the past 4 years and has been a valuable advisor to me in that role. Jim has a deep background in neuroscience drug development with over 35 years working specifically on CNS therapies. Prior to joining Trevy, Jim served as CDO for Concert Pharmaceuticals, which was acquired by Sun Pharma in 2023, where he led the development activities, resulting in the successful U. S. Speaker 100:02:42FDA approval of the autoimmune JAK inhibitor, Lexelvy. Prior to joining Concert, Jim was EVP Research and Development and CSO at Alexa Pharmaceuticals from 2,004 to 2015, where he was responsible for the U. S. And European approval of the CNS drug, Atasuv. Jim received a PhD in physiological psychology from Dartmouth College and completed a postdoctoral fellowship in the Department of Psychiatry at the Yale School of Medicine. Speaker 100:03:12Jim brings a wealth of development experience to Trevy, including Phase 3 and recent regulatory approval experience, which will be invaluable as we advance into late stage development. He joins Trevy at an exciting time as we read out important studies over the upcoming months and prepare for Phase 3 pivotal trials and NDA submission. So welcome, Jim. This has been a very productive quarter at Trevi as we continue to execute against our clinical development plans for both patients with chronic cough and idiopathic pulmonary fibrosis or IPF as well as patients with refractory chronic cough or RCC. We have a number of upcoming data readouts and we hope to build on the strong efficacy we saw in our Phase IIa trial in patients with IPF chronic cough. Speaker 100:03:59As we have advanced the clinical development in our 2 programs, there have been continued failures with competitors' products in both disease modification trials in IPF as well as drugs being studied in RCC, reminding us of the continued need for new therapies for patients suffering from these serious conditions. I will run through an update on our upcoming clinical data readouts, which I believe are seminal in value creation for the company. I will discuss them in order of timing. First up, the human abuse potential or HAP study. I have discussed this extensively with investors and analysts, so I'm sure you all feel you know more about HAP studies than you ever cared to. Speaker 100:04:40So let me summarize the key points on HAP as we prepare for data. As a reminder, injectable nalbutene, which is indicated for severe pain, has been around for decades and has remained unscheduled by the DEA. The DEA looks at scheduling of molecules regularly and schedules drugs based on the chemical entity, not the delivery mechanism. As recently as 2023, the date of their last review, the DEA has kept Nowbutene unscheduled. Importantly, I wanted to summarize for you their reasonings in their recent opinion. Speaker 100:05:13First is nowbutene's unique mechanism of action. Nowbutene is a kappa agonist and mu antagonist or KAMA, which is in the class of mixed agonist antagonist drugs. All drugs that are either a kappa agonist or a new antagonist are unscheduled and these were designed to mitigate abuse potential. 2nd, nalbutene is less attractive to abusers due to its potent antagonistic effects at new, which precipitate drug withdrawal. 3rd, even though nalbuphine is currently available, the DEA sites that nalbuphine is rarely encountered by law enforcement personnel or submitted to forensic labs for analysis. Speaker 100:05:54So there's a lot of history with nalbutene as a molecule and it is not new to the DEA. So why are we doing the HAP study at all? There is FDA guidance from 2017 that requires HAP studies for all CNS active drugs. So we are bringing the package up to current day standards. Finally, this study will be reviewed by the controlled substance staff, CFS, a group in FDA as part of the 8 factor plan. Speaker 100:06:21The 8 factor plan has several categories of which only one is the HAP. So we will wait to see the final data, but we believe there are a lot of reasons why nalbuphine will remain unscheduled if approved in chronic cough. Okay. Moving on to our clinical indications. Next up for data will be the sample size re estimation in our IPF cough trial. Speaker 100:06:43First, I want to note that new treatment options for IPF patients have been scarce since the anti fibrotics were approved 10 years ago. And neither of the 2 approved anti fibrotics have shown significant reduction in chronic costs. 2nd, other than our Phase 2 data, there have not been any successful trials in IPF cough despite being one of the primary complaints by these patients. And 3rd, we believe cough may be a risk factor that plays a role in the progression of the underlying disease. The constant lung injury, micro tears and potential inflammation caused by persistent coughing may lead to worse health outcomes for patients such as increased respiratory hospitalizations, mortality or need for transplant. Speaker 100:07:29So we continue to believe our program is important to these patients, their loved ones and doctors. Our IPF chronic cough trial, CORAL, is a Phase 2b parallel arm dose ranging study that will investigate 3 active doses of HEIDUVIO and placebo. The study is a 6 week trial in approximately 160 patients. The next milestone in CORAL is to conduct the sample size re estimation, SSRE analysis when 50% of the patients complete the study. This analysis will be done by an unblinded statistician external to the company who will rerun the power calculations using actual data. Speaker 100:08:10We will get very limited information back, but we'll be informed of one of the following three outcomes. 1, continue on with the planned 160 patients, which will reconfirm the original powering assumptions 2, the drug is working within the pre specified promising zone, but will require an upsize in the number of patients to maintain the power or 3, the drug is not working in the pre specified range and the company should consider stopping or futility. We will announce the results of this analysis when we have the information, which we expect in December of this year. We continue to expect top line data for the full study in the first half of twenty twenty five, subject to the outcome of the SSRE. From my perspective, the SSRE is a key derisking event for the ultimate success of this trial. Speaker 100:09:01If the answer back is anything but futility, the statistical range in this study, both the original and as well as the upper limit of the range is aligned to a clinically meaningful placebo adjusted change. So it is just a matter of figuring out the right sample size in this study population. Following the FSRE and IPF cough, we expect data in the Q1 of 2025 for our Phase 2a RIVER trial in RCC. RCC is a debilitating disease that affects approximately 2000000 to 3000000 U. S. Speaker 100:09:33Adults and is defined as a persistent cough lasting greater than 8 weeks despite treatment for an underlying condition or where no underlying condition exists. With a lack of any approved therapies for RCC in the U. S. And several drug candidate failures, there continues to be a significant unmet need and an urgency from patients and providers for new mechanisms. Although there have been many failures in RCC drug development, we believe our unique central and peripheral mechanism could change that outcome. Speaker 100:10:04The many drugs that have failed have all been peripheral only agents. The types of cough we are setting are linked through hypersensitivity in the brain and this is why we believe our mechanism may be important in this condition. Our RCC trial is a Phase 2a crossover design that has been conducted in several cough trials across the industry and was designed to enroll approximately 60 patients. These patients were randomized to nalbutene ER or placebo with patients stratified by cost count. Those with 10 to 19 cost per hour moderate cost and those with greater than or equal to 20 cost per hour high cost. Speaker 100:10:43The primary analysis will be conducted on the total population, we will have the ability to understand if our drug shows a signal in these moderate coffers where other programs have been unsuccessful. This trial is now fully enrolled with the last patient out at the beginning of 2025. We are excited to complete this study and report the data for this significant chronic cost condition in Q1 of 2025. As you can see, we made a lot of progress over the last few months on completing enrollment and dosing and are eager to see the data from each of these trials. To summarize, we expect HAP data in December of this year, followed by CORAL Phase 2b SSRE by year end as well. Speaker 100:11:28Then looking into 2025, we expect RIVER Phase 2a top line data in Q1 2025, then the top line data from the full coral Phase 2b study in first half twenty twenty five, assuming no increase in the sample size. This is an exciting time at Trevy with strong news flow in the upcoming months, all representing important value inflection points. I will now turn it over to Lisa to review our financial results. Speaker 200:11:54Thank you, Jennifer, and good afternoon, everyone. The full financial results for the 3 months ended September 30, 2024 can be found in our press release issued ahead of this call and our 10 Q, which was filed with the SEC today after the market closed. For the Q3 of 2024, we reported a net loss of $13,200,000 compared to a net loss of $7,700,000 for the same quarter in 2023. R and D expenses were $11,200,000 during the Q3 of 2024, compared to $6,300,000 in the same quarter of 2023. The increase in R and D spend reflects the significant clinical development activity Jennifer just discussed, including continued enrollment in our CORAL trial in chronic cough and IPF, the final full quarter of enrollment in the RIVER trial in RCC and the final full quarter of dosing in the HAP trial. Speaker 200:12:46G and A expenses were $2,900,000 during the Q3 of 2024 compared to $2,700,000 in the same period of 2023, primarily due to an increase in stock based compensation expense and importantly demonstrating the control of overhead expenses, which we continue to be mindful of. As of September 30, 2024, our cash, cash equivalents and marketable securities totaled $65,500,000 compared to $83,000,000 as of December 31, 2023. Our current expectation is that our cash burn for 2024, excluding proceeds from share issuances and interest and investment income will be between $41,000,000 $43,000,000 in line with our previous guidance. We now project cash runway into the second half of twenty twenty six more than a year past all current projected data readouts. This concludes our prepared remarks. Speaker 200:13:40I will now turn the call back over to the operator for Q and A. Operator00:13:47Thank you. We will now begin the question and answer session. And the first question will be from Faisal Kurschad from Leerink. Please go ahead. Speaker 300:14:35Hey, everyone. Thank you for taking the question. Also just wanted to say welcome to Jim and congrats on the new hire. Thanks Speaker 400:14:41so much. Speaker 300:14:43Yes. And just on the half, can you clarify, like what is your expectation for butorophenol drug liking and what's the evidence that supports that? And also, totally hear your point that drug scheduling considers the entire 8 factor analysis. But what do you want to see from nalbutene in the HAP to support an unscheduled designation as opposed to a potential Schedule 4? Speaker 100:15:06Thank you, Vasyl. I'm going to let Jim go ahead and take that. Speaker 400:15:10Yes. So thank you. It's nice to meet you and pleasure to be here for sure. So these are complicated studies and they involve experts running these things with subjects who have experience with the drug. Butorphanol is a drug that is scheduled for and has been abused by subjects. Speaker 400:15:33So we don't think we're well, we have to have patients qualify or subjects qualify to get into the study with betorphanol in a qualification period. So we are setting limits on their entry into the study where they have to have a certain criteria reached in an absolute sense as well as having a differentiation from placebo. So we know we're going to have effects on butorphanol or from butorphanol in this study and that is the part of the protocol that has been approved by the FDA. So when we look at this study and it's in the context of looking at scheduling in total at the end of the day, this study is really designed to look at a number of things with the primary endpoint, which is the VAS drug liking scale. We're looking to determine study validity by showing that butorphanol does differentiate from placebo and there's a fixed criteria of at least 15 points for that. Speaker 400:16:38We'll be looking at the relative abuse liability in terms of nalbuphine versus butorphanol. And in that, we'll be able to see if there is a lower relative abuse potential for nalbuphine by pre specified statistical endpoints determined and approved by the review by the FDA. And importantly, we'll be looking at the absolute abuse potential for nowbuphine in relationship to placebo. So in that case, we are able to determine within an equivalence margin that has been preset and again reviewed and approved by the FDA of 11 points within the placebo arm, we'll be able to determine for each dose whether or not we are significantly within that 11 point range from placebo. And if we are, then we'll be able to make a statement that we do not produce an abuse related signal compared to placebo. Speaker 400:17:47So those are the 3 outcomes using the primary efficacy endpoint of drug liking and we'll be able to take it from there as we look at the further evidence from the other endpoints in this study and put that in relationship to the whole package that we'll need to put in front of the FDA. That includes other things like experience from our other clinical trials and the other things that Jennifer has referred to from the most recent DSS analysis of nalbuphine. Speaker 300:18:21Got it. That's helpful. Thank you. Operator00:18:24And the next question will be from Leland Gershell from Oppenheimer. Please go ahead. Speaker 500:18:31Hey, thanks for the update and my welcome to Jim as well. Thanks for taking the questions. I'll try to keep it to 1, but maybe a multipart. Jen, just wanted to ask with respect to the SSRE, would there be a fixed increase in sample size that could be triggered if that's the outcome or would it be variable depending on how much you may need to prospectively increase the number of patients given both dynefin and have you shared what the fixed number would be if that's the case? Thank you. Speaker 100:19:05Yes. No, it's a good question, Leland. Thank you. So basically, the range that we pre specified for the SSRE is the original end of 160 and it can go up to a total end of 400. It is not a fixed increase. Speaker 100:19:22They're going to take the actual numbers seen through 50%, repower the study and give us an exact number. So it can be anywhere in that range between $164100 that they would come back with. Speaker 400:19:34And maybe just one other comment on that. So we will be looking at the conditional probability of our findings and then we'll be able to power up based on that. And again, it will be a sliding scale depending on what the conditional probability is that is determined by the SSRE. Speaker 500:19:57Thank you. I'll jump back in the queue. Speaker 100:19:59Thanks, Leland. Operator00:20:01The next question comes from Deb Chatterjee from Jones Trading. Please go ahead. Speaker 600:20:07Hi, thanks for taking my question. I might have missed it, but could you please confirm that in the RCC trial, the two arms, like of different degree of coffers are now balanced? Speaker 100:20:21Thanks, Deb and Jonna for the question. So she's asking about if they're both balanced, the 2 arms in the RCC trial since we finished enrollment? Speaker 400:20:29Yes, balanced in terms of the treatment assignment? Speaker 100:20:32I think she's talking about the stratification one Speaker 500:20:34to 1. Speaker 400:20:35Yes, sure. So the intention was to open up the trial to patients that were stratified on a cough count of 10 to 19 or greater than 20. We did increase the enrollment period to try to get more subjects in the moderate arm. We decided that we were going to cut it off at a certain point in time and not wait for the complete balancing. So and balancing the complete enrollment of that stratification factor. Speaker 400:21:07It doesn't really impact the overall analysis because the overall analysis is based on the number of people in the trial and not based on the subgroup analysis. So we're not concerned about that at all. And I think that it will be sufficient numbers in that group to allow us to look at future looking statistical analysis and planning for our greater Phase 2b or Phase 3 program. But I think we'll have sufficient numbers in there and that's why we decided to stop when we did. Speaker 600:21:37Okay. Thanks for the color. Speaker 500:21:39Sure. Speaker 100:21:40Thanks, Deb and John. And we're looking forward to your call. Operator00:21:44And our next question is from Mayank Mamtani from B. Riley. Please go ahead. Speaker 700:21:52Hi. Yes, this is William Wood on for Mayank today. Thank you for taking our questions and congrats on the strong queue. So just to sort of continue on with the HAP trial, I'm just kind of curious what would happen after you receive the results from the trial, maybe the next steps, would you essentially would you go directly Operator00:22:11to the FDA with those results Speaker 700:22:11or would this sort of be start with that, William. And Jim's obviously just joining us. So he may Speaker 100:22:24start with that, William. And Jim's obviously just joining us. So he may bring some different views. But we'll obviously get the data. We'll end up submitting the CSR and the results around that. Speaker 100:22:35We'll for sure discuss it in our end of Phase 2 meeting on the IPF trial and probably invite any comments back. But I would envision that we'll wrap that into our next FDA meeting, but we'll submit the results ahead of time. Absolutely. Speaker 400:22:49I mean, it's a standard type study for drugs like this. We'll submit the CSR and all the data to the FDA per usual timing. And this study doesn't really gate us in terms of looking at future efficacy studies in our indications. So this will be a matter of studies in our indications. So this will be a matter of more NDA than the process of actually conducting our clinical programs. Speaker 400:23:13Okay. So it wouldn't affect any Speaker 700:23:17of the ongoing trials either, just to confirm? No. No. Speaker 400:23:23No. And again, this is a one of many piece of information that is really weighed by the DEA in general. And I think we just want everyone to remember that nalbutene has been around for decades. It is unscheduled. It is the moiety, as Jennifer said, that is usually considered that is considered in the terms of scheduling. Speaker 400:23:50So this is a different formulation. We are catching up on bringing a half data into the realm for nowbuphine. So again, all these things are going to be taken into account as well as the experiences of our subjects in our clinical trial. So there's nothing here that is necessarily gating and these will all be taken into account in the NDA process for approval. Speaker 700:24:17Thank you very much. I appreciate you taking your questions. Speaker 100:24:20Thank you, William. Operator00:24:22The next question comes from Brandon Folkes from Rodman and Renshaw. Please go ahead. Speaker 800:24:28Hi. Thanks for taking my questions and congratulations on the update. Maybe just one from me. Any update on the timing of the TIDAL respiratory physiology study? When can we hear more about that study? Speaker 800:24:46And maybe the second part of that with Jim coming in, welcome Jim, great to have you on board. But do you still intend to run that study? Is this something that may be under review? Just any color on commitment and timing to that title study would be great. Thank you. Speaker 100:25:00Yes. I'll comment on the first two and then I'll let Jim answer. I don't think he has any different thoughts. So Brandon, as you know, we're running this study really just to be able to define our Phase 3 patient population and IPS specifically. There's a group of patients that have sleep disordered breathing that we've carved out in our prior two clinical studies because we wanted to answer some questions around that. Speaker 100:25:25So we are that study is enrolling, it's screening patients enrolling. The timing is we need that data by the time we go to our end of Phase 2 meeting on IPF, which will be sometime on the current schedule second half of next year. I think it's unblinded. I don't anticipate that we'll probably put out a lot of data until we get to the end and we actually can interpret all the results and sort of what it means for inclusion and exclusion. But Jim, I'll let you add any color. Speaker 100:25:53I don't think you have any different thoughts. Speaker 400:25:55No, there's no different thoughts there at all. I think this is a good informative study for us that will just help us make some decisions in the future. Speaker 800:26:04Thanks. And that's great to hear. Thank you for taking my question. Speaker 100:26:07Yes. Thank you, Brandon. Operator00:26:14The next question is from Brian Deshner from Raymond James. Please go ahead. Speaker 900:26:22Hi there. I'm curious as to the timeline for DEA to make a decision in the sort of once you have the HAP results in hand, their decision or even feedback from them on the potential for scheduling? And also curious what dose level the comparator betorphanol is being dosed at? Thank you. Speaker 100:26:44Yes. No, I can answer both those. The DEA process unfortunately comes in the if it comes at all. What happens is you submit your NDA, FDA will review all that with a consult with CSS. Sometimes it doesn't even get referred to DEA. Speaker 100:26:55They sort of consider everything, look at your data that you submitted and it never even goes to DEA. If it does, it does, it does look at your data that you submitted and it never even goes to DEA. If it does, it goes as part of the NDA process and then they'll schedule it as part of your approval. So it'll come sort of right after that. As for the dose that we're using in betorphanol, it's a 6 milligram infusion over the course of an hour. Speaker 100:27:20And there was a whole study that was done to sort of mimic the inhaled version of butorphanol that's on the market. We couldn't use that because that actually had a taste to it. So it was very hard to blind it. And so we ended up basically mimicking the PK of that through the 6 milligram infusion. But that was all signed off with the FDA as the right dosed. Speaker 400:27:44Got it. Thank you very much. Speaker 100:27:45Yes. You're welcome. Thank you. Operator00:27:48And I'm not showing any further questions at this time. This concludes our question and answer session. I would like to turn the conference back over to Jennifer Good for closing remarks. Speaker 100:27:58Thank you. We look forward to sharing the results of our various clinical trials with you in the near future. Thank you for joining today's call, and we are available after this call for any follow-up questions you may have. Operator00:28:10The conference call has now concluded. Thank you for attending today's presentation. You may now disconnect.Read morePowered by Conference Call Audio Live Call not available Earnings Conference CallTrevi Therapeutics Q3 202400:00 / 00:00Speed:1x1.25x1.5x2x Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Trevi Therapeutics Earnings HeadlinesNovo Nordisk A/S (NYSE:NVO) Earns "Market Perform" Rating from BMO Capital MarketsApril 19 at 3:02 AM | americanbankingnews.comNovo Nordisk Is Getting Absolutely DestroyedApril 19 at 1:25 AM | msn.comNew “Trump” currency proposed in DCAccording to one of the most connected men in Washington… A surprising new bill was just introduced in Washington. Its purpose: to put Donald Trump’s face on the $100 note. All to celebrate a new “golden age” for America. April 19, 2025 | Paradigm Press (Ad)Novo Nordisk: A Price Too Low To IgnoreApril 18 at 11:00 AM | seekingalpha.comNovo Nordisk A/S (NYSE:NVO) Receives Average Recommendation of "Hold" from AnalystsApril 18 at 2:49 AM | americanbankingnews.comNovo Nordisk downgraded by BMO as Eli Lilly gains ground in weight-loss drug raceApril 17 at 5:57 PM | finance.yahoo.comSee More Novo Nordisk A/S Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Trevi Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Trevi Therapeutics and other key companies, straight to your email. Email Address About Trevi TherapeuticsTrevi Therapeutics (NASDAQ:TRVI), a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapy Haduvio for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC) conditions targeting the central and peripheral nervous systems. The company is developing Haduvio, an oral extended-release formulation of nalbuphine, which is in phase 2b Cough Reduction in IPF with nalbuphine ER (CORAL) clinical trial for treatment of chronic cough in patients with IPF; phase 2a Refractory Chronic Cough Improvement Via NAL ER (RIVER) clinical trial for reducing chronic cough in RCC patients; phase 2 clinical trial in patients with pruritus; phase 2b/3 clinical trial in patients with prurigo nodularis. It has a license agreement with Endo Pharmaceuticals Inc. to develop and commercialize products incorporating nalbuphine hydrochloride in any formulation. The company was incorporated in 2011 and is headquartered in New Haven, Connecticut.View Trevi Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Archer Aviation Unveils NYC Network Ahead of Key Earnings Report3 Reasons to Like the Look of Amazon Ahead of EarningsTesla Stock Eyes Breakout With Earnings on DeckJohnson & Johnson Earnings Were More Good Than Bad—Time to Buy? Why Analysts Boosted United Airlines Stock Ahead of EarningsLamb Weston Stock Rises, Earnings Provide Calm Amidst ChaosIntuitive Machines Gains After Earnings Beat, NASA Missions Ahead Upcoming Earnings Tesla (4/22/2025)Intuitive Surgical (4/22/2025)Verizon Communications (4/22/2025)Canadian National Railway (4/22/2025)Novartis (4/22/2025)RTX (4/22/2025)3M (4/22/2025)Capital One Financial (4/22/2025)General Electric (4/22/2025)Danaher (4/22/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
There are 10 speakers on the call. Operator00:00:00Good afternoon, and welcome to the Trevi Therapeutics Third Quarter 2024 Earnings Conference Call. At this time, all participants will be in listen only mode. After today's presentation, there will be an opportunity to ask questions. Please note this event is being recorded. Various remarks that management makes during this conference call about the company's future expectations, plans and prospects constitute forward looking statements for purposes of the Safe Harbor provisions under the Private Securities Litigation Reform Act of 1995. Operator00:00:50Actual results may differ materially from those indicated by these forward looking statements as a result of various important factors, including those discussed in the Risk Factors section of the company's most recent quarterly report on Form 10 Q, which the company filed with the SEC this afternoon. In addition, any forward looking statements represent the company's views only as of today and should not be relied upon as representing the company's views as of any subsequent date. While the company may elect to update these forward looking statements at some point in the future, the company specifically disclaims any obligation to do so, even if its views change. I would now like to turn the conference call over to Jennifer Goode, Trevy's President and CEO. Please go ahead. Speaker 100:01:41Good afternoon, and thank you for joining us for our Q3 2024 earnings call and business update. Joining me today on this call are my colleagues Lisa Delfini, Trevy's Chief Financial Officer and Doctor. James Casella, Trevy's Chief Development Officer. I will give an update on our trials and upcoming data milestones and Lisa will give a brief financial update. Then the 3 of us are happy to answer any questions. Speaker 100:02:07First, I would like to take a minute and introduce you to Jim Casella, who has recently joined our leadership team as our Chief Development Officer. As some of you may know, Jim has been on our Board of Directors for the past 4 years and has been a valuable advisor to me in that role. Jim has a deep background in neuroscience drug development with over 35 years working specifically on CNS therapies. Prior to joining Trevy, Jim served as CDO for Concert Pharmaceuticals, which was acquired by Sun Pharma in 2023, where he led the development activities, resulting in the successful U. S. Speaker 100:02:42FDA approval of the autoimmune JAK inhibitor, Lexelvy. Prior to joining Concert, Jim was EVP Research and Development and CSO at Alexa Pharmaceuticals from 2,004 to 2015, where he was responsible for the U. S. And European approval of the CNS drug, Atasuv. Jim received a PhD in physiological psychology from Dartmouth College and completed a postdoctoral fellowship in the Department of Psychiatry at the Yale School of Medicine. Speaker 100:03:12Jim brings a wealth of development experience to Trevy, including Phase 3 and recent regulatory approval experience, which will be invaluable as we advance into late stage development. He joins Trevy at an exciting time as we read out important studies over the upcoming months and prepare for Phase 3 pivotal trials and NDA submission. So welcome, Jim. This has been a very productive quarter at Trevi as we continue to execute against our clinical development plans for both patients with chronic cough and idiopathic pulmonary fibrosis or IPF as well as patients with refractory chronic cough or RCC. We have a number of upcoming data readouts and we hope to build on the strong efficacy we saw in our Phase IIa trial in patients with IPF chronic cough. Speaker 100:03:59As we have advanced the clinical development in our 2 programs, there have been continued failures with competitors' products in both disease modification trials in IPF as well as drugs being studied in RCC, reminding us of the continued need for new therapies for patients suffering from these serious conditions. I will run through an update on our upcoming clinical data readouts, which I believe are seminal in value creation for the company. I will discuss them in order of timing. First up, the human abuse potential or HAP study. I have discussed this extensively with investors and analysts, so I'm sure you all feel you know more about HAP studies than you ever cared to. Speaker 100:04:40So let me summarize the key points on HAP as we prepare for data. As a reminder, injectable nalbutene, which is indicated for severe pain, has been around for decades and has remained unscheduled by the DEA. The DEA looks at scheduling of molecules regularly and schedules drugs based on the chemical entity, not the delivery mechanism. As recently as 2023, the date of their last review, the DEA has kept Nowbutene unscheduled. Importantly, I wanted to summarize for you their reasonings in their recent opinion. Speaker 100:05:13First is nowbutene's unique mechanism of action. Nowbutene is a kappa agonist and mu antagonist or KAMA, which is in the class of mixed agonist antagonist drugs. All drugs that are either a kappa agonist or a new antagonist are unscheduled and these were designed to mitigate abuse potential. 2nd, nalbutene is less attractive to abusers due to its potent antagonistic effects at new, which precipitate drug withdrawal. 3rd, even though nalbuphine is currently available, the DEA sites that nalbuphine is rarely encountered by law enforcement personnel or submitted to forensic labs for analysis. Speaker 100:05:54So there's a lot of history with nalbutene as a molecule and it is not new to the DEA. So why are we doing the HAP study at all? There is FDA guidance from 2017 that requires HAP studies for all CNS active drugs. So we are bringing the package up to current day standards. Finally, this study will be reviewed by the controlled substance staff, CFS, a group in FDA as part of the 8 factor plan. Speaker 100:06:21The 8 factor plan has several categories of which only one is the HAP. So we will wait to see the final data, but we believe there are a lot of reasons why nalbuphine will remain unscheduled if approved in chronic cough. Okay. Moving on to our clinical indications. Next up for data will be the sample size re estimation in our IPF cough trial. Speaker 100:06:43First, I want to note that new treatment options for IPF patients have been scarce since the anti fibrotics were approved 10 years ago. And neither of the 2 approved anti fibrotics have shown significant reduction in chronic costs. 2nd, other than our Phase 2 data, there have not been any successful trials in IPF cough despite being one of the primary complaints by these patients. And 3rd, we believe cough may be a risk factor that plays a role in the progression of the underlying disease. The constant lung injury, micro tears and potential inflammation caused by persistent coughing may lead to worse health outcomes for patients such as increased respiratory hospitalizations, mortality or need for transplant. Speaker 100:07:29So we continue to believe our program is important to these patients, their loved ones and doctors. Our IPF chronic cough trial, CORAL, is a Phase 2b parallel arm dose ranging study that will investigate 3 active doses of HEIDUVIO and placebo. The study is a 6 week trial in approximately 160 patients. The next milestone in CORAL is to conduct the sample size re estimation, SSRE analysis when 50% of the patients complete the study. This analysis will be done by an unblinded statistician external to the company who will rerun the power calculations using actual data. Speaker 100:08:10We will get very limited information back, but we'll be informed of one of the following three outcomes. 1, continue on with the planned 160 patients, which will reconfirm the original powering assumptions 2, the drug is working within the pre specified promising zone, but will require an upsize in the number of patients to maintain the power or 3, the drug is not working in the pre specified range and the company should consider stopping or futility. We will announce the results of this analysis when we have the information, which we expect in December of this year. We continue to expect top line data for the full study in the first half of twenty twenty five, subject to the outcome of the SSRE. From my perspective, the SSRE is a key derisking event for the ultimate success of this trial. Speaker 100:09:01If the answer back is anything but futility, the statistical range in this study, both the original and as well as the upper limit of the range is aligned to a clinically meaningful placebo adjusted change. So it is just a matter of figuring out the right sample size in this study population. Following the FSRE and IPF cough, we expect data in the Q1 of 2025 for our Phase 2a RIVER trial in RCC. RCC is a debilitating disease that affects approximately 2000000 to 3000000 U. S. Speaker 100:09:33Adults and is defined as a persistent cough lasting greater than 8 weeks despite treatment for an underlying condition or where no underlying condition exists. With a lack of any approved therapies for RCC in the U. S. And several drug candidate failures, there continues to be a significant unmet need and an urgency from patients and providers for new mechanisms. Although there have been many failures in RCC drug development, we believe our unique central and peripheral mechanism could change that outcome. Speaker 100:10:04The many drugs that have failed have all been peripheral only agents. The types of cough we are setting are linked through hypersensitivity in the brain and this is why we believe our mechanism may be important in this condition. Our RCC trial is a Phase 2a crossover design that has been conducted in several cough trials across the industry and was designed to enroll approximately 60 patients. These patients were randomized to nalbutene ER or placebo with patients stratified by cost count. Those with 10 to 19 cost per hour moderate cost and those with greater than or equal to 20 cost per hour high cost. Speaker 100:10:43The primary analysis will be conducted on the total population, we will have the ability to understand if our drug shows a signal in these moderate coffers where other programs have been unsuccessful. This trial is now fully enrolled with the last patient out at the beginning of 2025. We are excited to complete this study and report the data for this significant chronic cost condition in Q1 of 2025. As you can see, we made a lot of progress over the last few months on completing enrollment and dosing and are eager to see the data from each of these trials. To summarize, we expect HAP data in December of this year, followed by CORAL Phase 2b SSRE by year end as well. Speaker 100:11:28Then looking into 2025, we expect RIVER Phase 2a top line data in Q1 2025, then the top line data from the full coral Phase 2b study in first half twenty twenty five, assuming no increase in the sample size. This is an exciting time at Trevy with strong news flow in the upcoming months, all representing important value inflection points. I will now turn it over to Lisa to review our financial results. Speaker 200:11:54Thank you, Jennifer, and good afternoon, everyone. The full financial results for the 3 months ended September 30, 2024 can be found in our press release issued ahead of this call and our 10 Q, which was filed with the SEC today after the market closed. For the Q3 of 2024, we reported a net loss of $13,200,000 compared to a net loss of $7,700,000 for the same quarter in 2023. R and D expenses were $11,200,000 during the Q3 of 2024, compared to $6,300,000 in the same quarter of 2023. The increase in R and D spend reflects the significant clinical development activity Jennifer just discussed, including continued enrollment in our CORAL trial in chronic cough and IPF, the final full quarter of enrollment in the RIVER trial in RCC and the final full quarter of dosing in the HAP trial. Speaker 200:12:46G and A expenses were $2,900,000 during the Q3 of 2024 compared to $2,700,000 in the same period of 2023, primarily due to an increase in stock based compensation expense and importantly demonstrating the control of overhead expenses, which we continue to be mindful of. As of September 30, 2024, our cash, cash equivalents and marketable securities totaled $65,500,000 compared to $83,000,000 as of December 31, 2023. Our current expectation is that our cash burn for 2024, excluding proceeds from share issuances and interest and investment income will be between $41,000,000 $43,000,000 in line with our previous guidance. We now project cash runway into the second half of twenty twenty six more than a year past all current projected data readouts. This concludes our prepared remarks. Speaker 200:13:40I will now turn the call back over to the operator for Q and A. Operator00:13:47Thank you. We will now begin the question and answer session. And the first question will be from Faisal Kurschad from Leerink. Please go ahead. Speaker 300:14:35Hey, everyone. Thank you for taking the question. Also just wanted to say welcome to Jim and congrats on the new hire. Thanks Speaker 400:14:41so much. Speaker 300:14:43Yes. And just on the half, can you clarify, like what is your expectation for butorophenol drug liking and what's the evidence that supports that? And also, totally hear your point that drug scheduling considers the entire 8 factor analysis. But what do you want to see from nalbutene in the HAP to support an unscheduled designation as opposed to a potential Schedule 4? Speaker 100:15:06Thank you, Vasyl. I'm going to let Jim go ahead and take that. Speaker 400:15:10Yes. So thank you. It's nice to meet you and pleasure to be here for sure. So these are complicated studies and they involve experts running these things with subjects who have experience with the drug. Butorphanol is a drug that is scheduled for and has been abused by subjects. Speaker 400:15:33So we don't think we're well, we have to have patients qualify or subjects qualify to get into the study with betorphanol in a qualification period. So we are setting limits on their entry into the study where they have to have a certain criteria reached in an absolute sense as well as having a differentiation from placebo. So we know we're going to have effects on butorphanol or from butorphanol in this study and that is the part of the protocol that has been approved by the FDA. So when we look at this study and it's in the context of looking at scheduling in total at the end of the day, this study is really designed to look at a number of things with the primary endpoint, which is the VAS drug liking scale. We're looking to determine study validity by showing that butorphanol does differentiate from placebo and there's a fixed criteria of at least 15 points for that. Speaker 400:16:38We'll be looking at the relative abuse liability in terms of nalbuphine versus butorphanol. And in that, we'll be able to see if there is a lower relative abuse potential for nalbuphine by pre specified statistical endpoints determined and approved by the review by the FDA. And importantly, we'll be looking at the absolute abuse potential for nowbuphine in relationship to placebo. So in that case, we are able to determine within an equivalence margin that has been preset and again reviewed and approved by the FDA of 11 points within the placebo arm, we'll be able to determine for each dose whether or not we are significantly within that 11 point range from placebo. And if we are, then we'll be able to make a statement that we do not produce an abuse related signal compared to placebo. Speaker 400:17:47So those are the 3 outcomes using the primary efficacy endpoint of drug liking and we'll be able to take it from there as we look at the further evidence from the other endpoints in this study and put that in relationship to the whole package that we'll need to put in front of the FDA. That includes other things like experience from our other clinical trials and the other things that Jennifer has referred to from the most recent DSS analysis of nalbuphine. Speaker 300:18:21Got it. That's helpful. Thank you. Operator00:18:24And the next question will be from Leland Gershell from Oppenheimer. Please go ahead. Speaker 500:18:31Hey, thanks for the update and my welcome to Jim as well. Thanks for taking the questions. I'll try to keep it to 1, but maybe a multipart. Jen, just wanted to ask with respect to the SSRE, would there be a fixed increase in sample size that could be triggered if that's the outcome or would it be variable depending on how much you may need to prospectively increase the number of patients given both dynefin and have you shared what the fixed number would be if that's the case? Thank you. Speaker 100:19:05Yes. No, it's a good question, Leland. Thank you. So basically, the range that we pre specified for the SSRE is the original end of 160 and it can go up to a total end of 400. It is not a fixed increase. Speaker 100:19:22They're going to take the actual numbers seen through 50%, repower the study and give us an exact number. So it can be anywhere in that range between $164100 that they would come back with. Speaker 400:19:34And maybe just one other comment on that. So we will be looking at the conditional probability of our findings and then we'll be able to power up based on that. And again, it will be a sliding scale depending on what the conditional probability is that is determined by the SSRE. Speaker 500:19:57Thank you. I'll jump back in the queue. Speaker 100:19:59Thanks, Leland. Operator00:20:01The next question comes from Deb Chatterjee from Jones Trading. Please go ahead. Speaker 600:20:07Hi, thanks for taking my question. I might have missed it, but could you please confirm that in the RCC trial, the two arms, like of different degree of coffers are now balanced? Speaker 100:20:21Thanks, Deb and Jonna for the question. So she's asking about if they're both balanced, the 2 arms in the RCC trial since we finished enrollment? Speaker 400:20:29Yes, balanced in terms of the treatment assignment? Speaker 100:20:32I think she's talking about the stratification one Speaker 500:20:34to 1. Speaker 400:20:35Yes, sure. So the intention was to open up the trial to patients that were stratified on a cough count of 10 to 19 or greater than 20. We did increase the enrollment period to try to get more subjects in the moderate arm. We decided that we were going to cut it off at a certain point in time and not wait for the complete balancing. So and balancing the complete enrollment of that stratification factor. Speaker 400:21:07It doesn't really impact the overall analysis because the overall analysis is based on the number of people in the trial and not based on the subgroup analysis. So we're not concerned about that at all. And I think that it will be sufficient numbers in that group to allow us to look at future looking statistical analysis and planning for our greater Phase 2b or Phase 3 program. But I think we'll have sufficient numbers in there and that's why we decided to stop when we did. Speaker 600:21:37Okay. Thanks for the color. Speaker 500:21:39Sure. Speaker 100:21:40Thanks, Deb and John. And we're looking forward to your call. Operator00:21:44And our next question is from Mayank Mamtani from B. Riley. Please go ahead. Speaker 700:21:52Hi. Yes, this is William Wood on for Mayank today. Thank you for taking our questions and congrats on the strong queue. So just to sort of continue on with the HAP trial, I'm just kind of curious what would happen after you receive the results from the trial, maybe the next steps, would you essentially would you go directly Operator00:22:11to the FDA with those results Speaker 700:22:11or would this sort of be start with that, William. And Jim's obviously just joining us. So he may Speaker 100:22:24start with that, William. And Jim's obviously just joining us. So he may bring some different views. But we'll obviously get the data. We'll end up submitting the CSR and the results around that. Speaker 100:22:35We'll for sure discuss it in our end of Phase 2 meeting on the IPF trial and probably invite any comments back. But I would envision that we'll wrap that into our next FDA meeting, but we'll submit the results ahead of time. Absolutely. Speaker 400:22:49I mean, it's a standard type study for drugs like this. We'll submit the CSR and all the data to the FDA per usual timing. And this study doesn't really gate us in terms of looking at future efficacy studies in our indications. So this will be a matter of studies in our indications. So this will be a matter of more NDA than the process of actually conducting our clinical programs. Speaker 400:23:13Okay. So it wouldn't affect any Speaker 700:23:17of the ongoing trials either, just to confirm? No. No. Speaker 400:23:23No. And again, this is a one of many piece of information that is really weighed by the DEA in general. And I think we just want everyone to remember that nalbutene has been around for decades. It is unscheduled. It is the moiety, as Jennifer said, that is usually considered that is considered in the terms of scheduling. Speaker 400:23:50So this is a different formulation. We are catching up on bringing a half data into the realm for nowbuphine. So again, all these things are going to be taken into account as well as the experiences of our subjects in our clinical trial. So there's nothing here that is necessarily gating and these will all be taken into account in the NDA process for approval. Speaker 700:24:17Thank you very much. I appreciate you taking your questions. Speaker 100:24:20Thank you, William. Operator00:24:22The next question comes from Brandon Folkes from Rodman and Renshaw. Please go ahead. Speaker 800:24:28Hi. Thanks for taking my questions and congratulations on the update. Maybe just one from me. Any update on the timing of the TIDAL respiratory physiology study? When can we hear more about that study? Speaker 800:24:46And maybe the second part of that with Jim coming in, welcome Jim, great to have you on board. But do you still intend to run that study? Is this something that may be under review? Just any color on commitment and timing to that title study would be great. Thank you. Speaker 100:25:00Yes. I'll comment on the first two and then I'll let Jim answer. I don't think he has any different thoughts. So Brandon, as you know, we're running this study really just to be able to define our Phase 3 patient population and IPS specifically. There's a group of patients that have sleep disordered breathing that we've carved out in our prior two clinical studies because we wanted to answer some questions around that. Speaker 100:25:25So we are that study is enrolling, it's screening patients enrolling. The timing is we need that data by the time we go to our end of Phase 2 meeting on IPF, which will be sometime on the current schedule second half of next year. I think it's unblinded. I don't anticipate that we'll probably put out a lot of data until we get to the end and we actually can interpret all the results and sort of what it means for inclusion and exclusion. But Jim, I'll let you add any color. Speaker 100:25:53I don't think you have any different thoughts. Speaker 400:25:55No, there's no different thoughts there at all. I think this is a good informative study for us that will just help us make some decisions in the future. Speaker 800:26:04Thanks. And that's great to hear. Thank you for taking my question. Speaker 100:26:07Yes. Thank you, Brandon. Operator00:26:14The next question is from Brian Deshner from Raymond James. Please go ahead. Speaker 900:26:22Hi there. I'm curious as to the timeline for DEA to make a decision in the sort of once you have the HAP results in hand, their decision or even feedback from them on the potential for scheduling? And also curious what dose level the comparator betorphanol is being dosed at? Thank you. Speaker 100:26:44Yes. No, I can answer both those. The DEA process unfortunately comes in the if it comes at all. What happens is you submit your NDA, FDA will review all that with a consult with CSS. Sometimes it doesn't even get referred to DEA. Speaker 100:26:55They sort of consider everything, look at your data that you submitted and it never even goes to DEA. If it does, it does, it does look at your data that you submitted and it never even goes to DEA. If it does, it goes as part of the NDA process and then they'll schedule it as part of your approval. So it'll come sort of right after that. As for the dose that we're using in betorphanol, it's a 6 milligram infusion over the course of an hour. Speaker 100:27:20And there was a whole study that was done to sort of mimic the inhaled version of butorphanol that's on the market. We couldn't use that because that actually had a taste to it. So it was very hard to blind it. And so we ended up basically mimicking the PK of that through the 6 milligram infusion. But that was all signed off with the FDA as the right dosed. Speaker 400:27:44Got it. Thank you very much. Speaker 100:27:45Yes. You're welcome. Thank you. Operator00:27:48And I'm not showing any further questions at this time. This concludes our question and answer session. I would like to turn the conference back over to Jennifer Good for closing remarks. Speaker 100:27:58Thank you. We look forward to sharing the results of our various clinical trials with you in the near future. Thank you for joining today's call, and we are available after this call for any follow-up questions you may have. Operator00:28:10The conference call has now concluded. Thank you for attending today's presentation. You may now disconnect.Read morePowered by